<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.

Simple item page
dc.authorid0000-0001-9636-4113
dc.contributor.authorSevindik, Ömür Gökmen
dc.contributor.authorChen, Chang
dc.contributor.authorYang, Jing
dc.contributor.authorFarooqui, Mohammed Z. H.
dc.contributor.authorPaszkiewicz-Kozik, Ewa
dc.date.accessioned2024-03-13T10:16:53Z
dc.date.available2024-03-13T10:16:53Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipMerck & Companyen_US
dc.identifier.citationSevindik, Ö. G., Chen, C., Yang, J., Farooqui, M. Z. H. ve Paszkiewicz-Kozik, E. (2023). BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12364
dc.identifier.volume41
dc.identifier.wos001053772005459en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorSevindik, Ömür Gökmen
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO)en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSmall Lymphocytic Lymphoma (SLL)
dc.subjectChronic Lymphocytic Leukemia (CLL)
dc.subjectUntreated Patients
dc.titleBELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
dc.typeConference Object

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu